These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38924336)

  • 1. Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    Diabetes Obes Metab; 2024 Jun; ():. PubMed ID: 38924336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Sep; 14(9):1101-1109. PubMed ID: 37264517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
    Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
    Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
    Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Dubourg J; Ueki K; Grouin JM; Fouqueray P
    Diabetes Obes Metab; 2021 Mar; 23(3):800-810. PubMed ID: 33275318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38794986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Hagi K; Nitta M; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Nov; 14(11):1246-1261. PubMed ID: 37610062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
    Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
    BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
    Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
    Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
    Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
    Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
    Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
    Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
    Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
    Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and complication rates in type 2 diabetes mellitus clusters on five variables: glycated hemoglobin, age at diagnosis, body mass index, HOMA-IR, HOMA-B].
    Bondar IA; Shabelnikova OY
    Probl Endokrinol (Mosk); 2023 Nov; 69(5):84-92. PubMed ID: 37968955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes classification: a data-driven cluster study of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort.
    Christensen DH; Nicolaisen SK; Ahlqvist E; Stidsen JV; Nielsen JS; Hojlund K; Olsen MH; García-Calzón S; Ling C; Rungby J; Brandslund I; Vestergaard P; Jessen N; Hansen T; Brøns C; Beck-Nielsen H; Sørensen HT; Thomsen RW; Vaag A
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35428673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
    Osonoi T; Shirabe S; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
    Front Pharmacol; 2023; 14():1205021. PubMed ID: 37351507
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data.
    Zou X; Huang Q; Luo Y; Ren Q; Han X; Zhou X; Ji L
    Diabetologia; 2022 Sep; 65(9):1424-1435. PubMed ID: 35802168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
    Blonde L; Fainberg U; Kaltoft MS; Mosenzon O; Ramesh C; Rea R
    Diabetes Obes Metab; 2021 Oct; 23(10):2234-2241. PubMed ID: 34132018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.